January 9, 2020 / 6:54 AM / 10 days ago

BRIEF-Novartis: Ligelizumab More Effective Than Xolair At Inhibiting Immunoglobulin E Pathway

Jan 9 (Reuters) - Novartis AG:

* LIGELIZUMAB (QGE031) MORE EFFECTIVE THAN XOLAIR® AT INHIBITING IMMUNOGLOBULIN E PATHWAY RESPONSIBLE FOR CHRONIC SPONTANEOUS URTICARIA

* DATA SHOW LIGELIZUMAB AND XOLAIR RECOGNIZE AND BIND DIFFERENTLY TO IGE, WITH LIGELIZUMAB RESULTING IN A SIGNIFICANTLY ENHANCED BLOCKADE OF IGE/FCΕRI SIGNALING Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below